Renaissance Capital logo

DMTX News

Making rare diseases rarer: Gene therapy biotech AveXis sets terms for $85 million IPO

Dimension Therapeutics logo

AveXis, an early-stage biotech developing gene therapies for rare neurological diseases, announced terms for its IPO on Monday. The Bannockburn, IL-based company plans to raise $85 million by offering 4.25 million shares at a price range of $19 to $21....read more

US IPO Weekly Recap: The only IPO delays as the market falls for the second straight week

PLXP

A bad start to the year only got worse this week as the S&P 500 fell another 2%. For the first time since October, the ninety-day returns swung negative to -0.6%. Just two weeks ago, that number stood at 17%. The VIX is up 48% year-to-date, closing...read more

US IPO Weekly Recap: Paper gains for a paper packaging producer

RACE

Pricing pressure continued this week as only one company was able to price in or above its range. Five IPOs raised $1.2 billion this week, including one of the most highly-anticipated IPOs of 2015. However, it was a global print packaging...read more

Dimension Therapeutics prices IPO at $13.00, below the range

Dimension Therapeutics logo

Dimension Therapeutics, which is developing novel, liver-directed gene therapies for rare genetic disorders, raised $72 million on Wednesday by offering 5.5 million shares at $13, below the range of $14 to $16. This gives the company a market cap of $355...read more